Peripheral Neuropathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Women aged 18 or older
- People who have recently had surgery for primary breast cancer (cancer that has not spread to other parts of the body) and are receiving follow-up chemotherapy that includes a drug called paclitaxel
- People whose only prior chemotherapy (before paclitaxel treatment) was cyclophosphamide and epirubicin
- People whose general health and ability to carry out daily activities is rated at a good to fully active level (known as ECOG performance status 0–1 — confirm with trial site if unsure what this means for a specific situation)
- People who are willing and able to sign a consent form, communicate with the research team, attend assessments, and follow the study requirements
Who may not be able to join:
- People who have taken medications known or suspected to cause nerve damage
- People with a personal or family history of nerve damage conditions, or a genetic condition that increases the chance of developing nerve problems
- People with a known problem with blood sugar regulation, such as diabetes or pre-diabetes
- People with moderate to severe disease affecting the kidneys, liver, lungs, or heart
- People with known spinal stenosis (narrowing of the spinal canal) that causes symptoms or is considered advanced
- People with a known autoimmune disease that could cause or contribute to nerve damage
- People with a known HIV infection, or an active hepatitis B or hepatitis C infection
- People with a known paraneoplastic syndrome (a condition where the immune system's response to cancer affects the nervous system — confirm with trial site)
- People with a known alcohol use problem
- People who are pregnant or currently breastfeeding
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Theodoros Foukakis, MD, PhD, Karolinska University Hospital
Phone: 0736896713
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Correlation of significant deterioration in neurophysiological parameters including alterations in morphology of small fibers or reduced IENFD (Intraepidermal Nerve Fiber Density) on first follow up visit and development of CIPN; Correlation of abnormal laboratory tests in baseline assessment with development/severity of CIPN; Correlation of parameters of NCS, temperature thresholds, and IENFD at baseline screening with development and severity of CIPN; Biochemical and metabolic abnormalities prior to paclitaxel treatment and their association with the development of CIPN
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.